1. Home
  2. Products
  3. Customized ADCs
  4. TNFRSF8
  5. Anti-TNFRSF8 (Brentuximab)-VC-PAB-MMAE ADC

Anti-TNFRSF8 (Brentuximab)-VC-PAB-MMAE ADC (CAT#: ADC-W-465)

This ADC product is comprised of an Anti-TNFRSF8 antibody (Brentuximab) conjugated via a VC-PAB linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • Product Information
  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Similar to
  • Brentuximab Vedotin
  • Name
  • TNFRSF8
  • Alternative Names
  • TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30;
  • Target Entrez Gene ID
  • 943
  • Overview
  • The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
  • Overview
  • Anti-TNFRSF8 Antibody, Brentuximab
  • Generic name
  • Brentuximab
  • Species Reactivity
  • Human
  • Name
  • VC-PAB (valine-citrulline with PAB)
  • Description
  • Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
  • Name
  • MMAE (Monomethyl auristatin E)
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-465. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Payload
CAT# Product Name Linker Payload
ADC-W-1890 Anti-TNFRSF8 (Iratumumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2347 Anti-TNFRSF8 (Brentuximab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1886 Anti-TNFRSF8 (Iratumumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-2345 Anti-TNFRSF8 (Brentuximab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-354 Anti-TNFRSF8 (clone Ki4) scFv-MAP ADC human pro-apoptotic effector protein, microtubule-associated protein tau (MAPT)
CAT# Product Name Linker Payload
ADC-W-536 Anti-EDNRB (endothelin B)-VC-MMAE ADC VC (valine-citrulline) MMAE (Monomethyl auristatin E)
ADC-AA-003 anti-HIgG(Fc)-C-MMAE ADC Cleavable linkers MMAE (Monomethyl auristatin E)
ADC-W-462 Anti-GPNMB-VC-MMAE ADC VC (valine-citrulline) MMAE (Monomethyl auristatin E)
ADC-AA-021 anti-MIgG(Fc)-C-MMAE ADC Cleavable linkers MMAE (Monomethyl auristatin E)
ADC-W-499 Anti-SLC34A2 (Lifastuzumab)-VC-MMAE ADC mc-VC-PABC MMAE (Monomethyl auristatin E)

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.